Allarity to present Phase 2 stenoparib trial poster at ESMO congress
Allarity Therapeutics will present a Trial-in-Progress poster on its Phase 2 stenoparib study for platinum-resistant ovarian cancer at the ESMO Gynaecological Cancers Congress in Copenhagen. The presentation showcases the clinical rationale for the dual PARP and WNT pathway inhib
View filing at SEC.gov →